Company Bellerophon Therapeutics, Inc. Börse Stuttgart
Equities
6L7A
US0787713009
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.421 EUR | +20.98% |
|
+26.05% | -45.08% |
05-02 | North American Morning Briefing : Stock Futures -2- | DJ |
04-25 | North American Morning Briefing : More Tech -2- | DJ |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Craig Jalbert
CEO | Chief Executive Officer | 63 | - |
Martin Dekker
CTO | Chief Tech/Sci/R&D Officer | 51 | 28/01/15 |
Edwin L. Parsley
CTO | Chief Tech/Sci/R&D Officer | 63 | - |
Bobae Kim
LAW | General Counsel | 42 | 31/08/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Naseem Amin
CHM | Chairman | 62 | 28/06/15 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 12,232,648 | 10,394,477 ( 84.97 %) | 0 | 84.97 % |
Company contact information
Bellerophon Therapeutics, Inc.
184 Liberty Corner Road Suite 302
07059, Warren
+908 574 4770
http://www.bellerophon.com![address Bellerophon Therapeutics, Inc.(6L7A)](https://cdn.zonebourse.com/static/address/54039154.png)
Sector
![Consensus](/images/consensus_flch.gif)
1st Jan change | Capi. | |
---|---|---|
+16.44% | 122B | |
+18.94% | 114B | |
+19.62% | 25.71B | |
-25.37% | 19.02B | |
-20.21% | 15.83B | |
-20.20% | 15.32B | |
-47.37% | 14.88B | |
+59.91% | 14.82B | |
+4.35% | 14.1B |
- Stock Market
- Equities
- BLPH Stock
- 6L7A Stock
- Company Bellerophon Therapeutics, Inc.